Answers are grounded in this paper and cite their sources.
GBA1 variants are major Parkinson's disease risk factors, but their detection is challenging. We compared NeuroBooster Array (NBA) genotyping with reference sequencing in 3,744 individuals. NBA correctly identified 520/608 carriers (85.5%). Of 89 missed calls, 73 had no matching probe and 16 had missing calls. 25 participants had false positive calls. NBA should not be used alone for clinical decisions, but is very useful for case control analysis.
No takes yet. Share an insight, caveat, or question.
Toffoli et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: